Intralymphatic immunotherapy for house dust mite allergic rhinitis, a pilot study

Phase 1

• Conditions: Allergic rhinitis; Allergic specific immunotherapy; Intralymphatic immunotherapy; ILIT; House dust mite allergy; Dysfunctional regulatory T cell

• Registration Number: TCTR20220725001
• Lead Sponsor: Phramongkutklao hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-25
• Study Completion: 2023-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Age 20-65 years with house dust mite allergic rhinitis and/or asthma

Exclusion Criteria

Previous AIT
Pregnancy/breastfeeding
Comorbidities: Uncontrolled cardiovascular disease, uncontrolled asthma, severe renal impairment, active liver disease, malignancy, autoimmune disease
Idiopathic anaphylaxis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptoms score At week 0,8, and 16 Description,Medication score At week 0, 8, and 16 Description

Secondary Outcome Measures

Name	Time	Method
Dysfunctional regulatory T cell At week 0, 8, and 16 Flow cytometry,Specific IgE and IgG4 At week 0, 8, and 16 ELISA